Journal
ARCHIVES OF MEDICAL RESEARCH
Volume 52, Issue 1, Pages 15-24Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.arcmed.2020.09.010
Keywords
SARS-CoV-2; COVID-19; Spike protein; Coronavirus; Drugs; Vaccine
Categories
Ask authors/readers for more resources
The COVID-19 pandemic has spurred the development of various drugs and vaccines worldwide, utilizing small-molecule drugs, vaccines, and immunoinformatics. While many vaccines are in clinical trials, mRNA and DNA vaccines still await regulatory approval.
The Coronavirus disease 2019 (COVID-19) pandemic has spread to almost all nooks and corners of the world. There are numerous potential approaches to pharmacologically fight COVID-19: small-molecule drugs, interferon therapies, vaccines, oligonucleotides, peptides, and monoclonal antibodies. Medications are being developed to target the spike, membrane, nucleocapsid or envelope proteins. The spike protein is also a critical target for vaccine development. Immunoinformatic approaches are being used for the identification of B cell and cytotoxic T lymphocyte (CTL) epitopes in the SARS-CoV-2 spike protein. Different vaccine vectors are also being developed. Chemical and physical methods such as formaldehyde, UV light or b-propiolactone are being deployed for the preparation of inactivated virus vaccine. Currently, there are many vaccines undergoing clinical trials. Even though mRNA and DNA vaccines are being designed and moved into clinical trials, these types of vaccines are yet to be approved by regulatory bodies for human use. This review focuses on the drugs and vaccines being developed against the COVID-19. (C) 2020 IMSS. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available